Shandong Sinobioway Biomedicine Co Ltd (002581) — Working Capital to Net Assets Ratio
Shandong Sinobioway Biomedicine Co Ltd (002581) has a Working Capital to Net Assets ratio of 30.0% as of September 2025. Working capital of CN¥597.91 Million (current assets of CN¥784.85 Million minus current liabilities of CN¥186.94 Million) is measured against net assets of CN¥1.99 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shandong Sinobioway Biomedicine Co Ltd (002581) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shandong Sinobioway Biomedicine Co Ltd Working Capital to Net Assets (2007–2024)
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 30.0%, reflecting working capital of CN¥597.91 Million against net assets of CN¥1.99 Billion CNY. For the complete balance sheet picture, see Shandong Sinobioway Biomedicine Co Ltd total assets.
Annual Working Capital to Net Assets for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Shandong Sinobioway Biomedicine Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 32.9% | CN¥664.40 Million | CN¥2.02 Billion | CN¥747.01 Million | CN¥82.61 Million | ▲ +16.1 pp |
| 2023 | 16.7% | CN¥363.10 Million | CN¥2.17 Billion | CN¥496.71 Million | CN¥133.61 Million | ▲ +10.5 pp |
| 2022 | 6.2% | CN¥154.08 Million | CN¥2.47 Billion | CN¥518.36 Million | CN¥364.28 Million | ▼ -6.3 pp |
| 2021 | 12.6% | CN¥309.91 Million | CN¥2.47 Billion | CN¥568.45 Million | CN¥258.54 Million | ▼ -13.0 pp |
| 2020 | 25.5% | CN¥559.30 Million | CN¥2.19 Billion | CN¥766.16 Million | CN¥206.87 Million | ▼ -39.8 pp |
| 2019 | 65.4% | CN¥1.56 Billion | CN¥2.39 Billion | CN¥1.80 Billion | CN¥239.52 Million | ▼ -15.3 pp |
| 2018 | 80.7% | CN¥2.28 Billion | CN¥2.82 Billion | CN¥2.84 Billion | CN¥565.56 Million | ▼ -4.1 pp |
| 2017 | 84.8% | CN¥2.47 Billion | CN¥2.92 Billion | CN¥2.73 Billion | CN¥256.84 Million | ▲ +29.9 pp |
| 2016 | 54.9% | CN¥1.39 Billion | CN¥2.53 Billion | CN¥1.51 Billion | CN¥128.39 Million | ▼ -0.4 pp |
| 2015 | 55.3% | CN¥1.18 Billion | CN¥2.14 Billion | CN¥1.42 Billion | CN¥235.23 Million | ▼ -18.8 pp |
| 2014 | 74.0% | CN¥554.77 Million | CN¥749.40 Million | CN¥572.65 Million | CN¥17.88 Million | ▲ +0.4 pp |
| 2013 | 73.6% | CN¥543.24 Million | CN¥738.31 Million | CN¥576.53 Million | CN¥33.29 Million | ▼ -3.0 pp |
| 2012 | 76.6% | CN¥539.76 Million | CN¥704.41 Million | CN¥562.17 Million | CN¥22.42 Million | ▼ -7.6 pp |
| 2011 | 84.2% | CN¥565.93 Million | CN¥672.28 Million | CN¥583.84 Million | CN¥17.91 Million | ▲ +32.1 pp |
| 2010 | 52.1% | CN¥92.40 Million | CN¥177.34 Million | CN¥124.74 Million | CN¥32.34 Million | ▲ +1.4 pp |
| 2009 | 50.7% | CN¥65.73 Million | CN¥129.71 Million | CN¥100.97 Million | CN¥35.24 Million | ▲ +6.2 pp |
| 2008 | 44.5% | CN¥51.63 Million | CN¥116.12 Million | CN¥79.04 Million | CN¥27.41 Million | ▼ -8.8 pp |
| 2007 | 53.2% | CN¥44.67 Million | CN¥83.94 Million | CN¥56.27 Million | CN¥11.60 Million | — |